Angion Biomedica Corp.: insider trades · United States · SEC (Form 4)

About Angion Biomedica Corp.

Angion Biomedica Corp. is a former U.S. biopharmaceutical company that was listed on the NASDAQ under the ticker ANGN and was originally based in the United States. The company was incorporated in Delaware in 1998 and built its early research and discovery footprint in Uniondale, New York, before later shifting its operational center of gravity toward Boston, Massachusetts after a major corporate combination. For investors, Angion should be understood less as a conventional commercial-stage drug company and more as a clinical-development platform focused on small-molecule therapeutics for acute organ injury and fibrotic disease. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1601485/000114036123020658/ny20006674x16_s4a.htm?utm_source=openai)) Historically, Angion’s R&D pipeline centered on several product candidates and programs. The best-known assets were ANG-3777, a hepatocyte growth factor (HGF) mimetic aimed at acute organ injury settings, and ANG-3070, an oral, highly selective kinase inhibitor being developed for fibrotic diseases, especially kidney and lung indications. The company also pursued additional preclinical programs, including ROCK2, CYP11B2, and CYP26-related efforts, which reflected a broader pipeline strategy rather than a single-asset story. Over time, however, the clinical path proved challenging, and some programs were discontinued, including the JUNIPER Phase 2 trial in 2022. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1601485/000160148523000011/angn-20221231.htm?utm_source=openai)) From a competitive standpoint, Angion operated in a highly demanding segment of biotechnology where scientific differentiation, clinical data quality, and financing access are critical. Its value proposition was based on potentially first-in-class or highly differentiated therapies for diseases with significant unmet medical need, but the company also faced the typical biotech constraints: long development timelines, binary trial risk, regulatory uncertainty, and dependence on capital markets. The available SEC disclosures also indicate that the business had not generated product revenue and had spent most of its resources on research and development, intellectual property, organization, and clinical execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1601485/000160148521000007/angn-12312020x10k.htm?utm_source=openai)) A key point for current analysis is that Angion is no longer an independent operating company. On June 1, 2023, Angion completed a reverse merger with Elicio Therapeutics and changed its name to Elicio Therapeutics, Inc. The combined company’s principal executive office is in Boston, Massachusetts. As a result, the Angion name today is mainly relevant for historical SEC records, legacy securities analysis, and prior insider transaction filings rather than as a standalone public biotech franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000062/angn-20250409.htm?utm_source=openai)) In terms of recent milestones, the SEC record shows a sequence of strategic reviews, program discontinuations, and the eventual merger transaction, which effectively reset the corporate identity. For investors tracking Form 4 insider transactions, this is important context: the economic story embedded in the legacy ANGN ticker was transformed by the 2023 merger, so any fundamental read-through should focus on the post-merger entity rather than on Angion as an independent biotech. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/angion-hangs-sale-sign-stops-drug-development-work-after-flops-force-search-exit?utm_source=openai))